Agrogen Limited
Registered name: AGROGEN LIMITED
Part of Vngif Artemis Bidco S.A.R.L groupAgrogen Limited made a £1.2m loss in the year to 31 Dec 2025 (revenue not disclosed).
Agrogen Limited reported a loss of £1.2m in the year to 31 Dec 2025; its revenue was not disclosed. It had 0 employees. The company is classified under “research and experimental development on biotechnology” and is based in Liverpool; we hold 4 years of its filed accounts.
- Status
- Active
- Location
- Liverpool, North West
- Age
- 13 yrs · since 2013
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.
Key figures
This company published its profit but not its turnover, so revenue and margins are not disclosed. We never estimate them.
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 30 Sep 2022 | 30 Sep 2023 | 30 Sep 2024 | 31 Dec 2025 |
|---|---|---|---|---|
| Disclosure | No P&L | No P&L | Profit only | Profit only |
| Profit & loss | ||||
| Revenue (turnover) | — | — | — | — |
| Profit after tax | — | — | −£84k | −£1.2m |
| Profit (best available) | — | — | −£84k | −£1.2m |
| Employees (average) | — | 0 | 0 | 0 |
| Ratios | ||||
| Profit margin | — | — | — | — |
| Balance sheet — indirect signals, not revenue | ||||
| Cash at bank | £24.3k | £89.9k | £44.5k | £12.1k |
| Net assets | −£188k | £93.3k | £9.3k | −£2.3m |
| Fixed assets | £2.5m | £2.3m | £2m | £838k |
| Current assets | £621k | £925k | £694k | £187k |
| Debtors | £554k | £795k | £80.8k | £6.9k |
| Source | AbridgedAccounts · bulk data Jun 2024 | AbridgedAccounts · bulk data Jun 2024 | AbridgedAccounts · bulk data Aug 2025 | FullAccounts · bulk data Sep 2026 |
How the business works
- Profit margin
- —
- Profit ÷ revenue.
- Gross margin
- —
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- —
- Revenue ÷ average employees.
- Profit per employee
- —
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- —
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now −£2.3m
- Cash at bank
- —
- Now £12.1k
- Headcount
- —
- Now 0
- Deferred income
- —
- Now —
- Fixed assets
- —
- Now £838k
Group structure
Ownership chain
- Vngif Artemis Bidco S.A.R.L (registered outside the UK register)ultimate parent75–100%
- UK Artemis Holdco Limited75–100%
- Eag Bioenergy NO.2 Limited75–100%
- Eag NO.2 Limited75–100%
- Agrogen Limitedthis company
Bands show the share of ownership each company holds in the one below it.
Sister companies (3)
- Beverley Bioenergy LtdFigures not disclosed
- Sprucefield Bioenergy LtdFigures not disclosed
- Thornfield 003 LimitedRev. — · Profit −£1m
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Astex Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £404m
- Profit
- £283m
- Staff
- 183
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Qiagen Manchester LimitedManchester · Research and experimental development on biotechnology
- Revenue
- £53.7m
- Profit
- £11.8m
- Staff
- 239
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
Sources
Latest figures from FullAccounts for the year to 31 Dec 2025 (profit −£1.2m), from the Companies House accounts bulk data published Sep 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.